BRNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Barinthus Biotherapeutics PLC (BRNS) is not a good buy for a beginner investor with a long-term horizon. The stock shows weak technical indicators, poor financial performance, no positive news or catalysts, and no significant trading trends. Additionally, there are no signals from Intellectia Proprietary Trading Signals to suggest a strong buy opportunity.
The technical indicators for BRNS are bearish. The MACD is negatively expanding below zero, the RSI is neutral but leaning towards oversold territory, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key support levels are at 0.538 and 0.499, indicating potential downside risk.
NULL identified. There is no recent news, no significant trading trends from hedge funds or insiders, and no recent Congress trading data.
The stock has shown a pre-market decline of -5.16% and a regular market decline of -0.04%. Financial performance is weak with declining net income (-46.01% YoY), EPS (-47.06% YoY), and gross margin (-100.00% YoY). Technical indicators are bearish, and there is no positive sentiment from news or trading trends.
In Q4 2025, the company reported zero revenue growth, a net income loss of -$11.09M (down 46.01% YoY), and a significant drop in EPS (-47.06% YoY). Gross margin fell to 0, indicating severe profitability challenges.
No data on analyst ratings or price target changes is available.
